Sovereign-scale verification for the GLP-1, CGM, and amputation-prevention frontier.
Diabetes is a $80B+ category moving through the most consequential therapeutic and reimbursement reset in a generation. GLP-1 and SGLT2 reimbursement decisions in flight through 2025–2026 are reshaping the next $40B in run-rate. Continuous glucose monitoring and automated insulin delivery are crossing into sovereign procurement. The Kingdom of Saudi Arabia carries an 18% diabetes prevalence — one of the highest globally — and has named lower-extremity amputation reduction a Vision 2030 priority. AimwellBio runs adversarial verification across every signal so investors, strategy teams, and ministries operate on cited intelligence — not generative assumptions.
Adversarial verification is the cost of being early.
Semaglutide and tirzepatide are reshaping the diabetes, obesity, and cardiometabolic markets simultaneously. Reimbursement decisions in flight through 2025–2026 will determine which manufacturers capture the next $40B in run-rate. Models built on prior formulary assumptions are silently breaking. AimwellBio tracks every payer revision, AdComm calendar item, and label expansion against the companies under your coverage.
The Kingdom of Saudi Arabia carries an 18% diabetes prevalence — one of the highest globally — and the Ministry of Health has positioned diabetic foot ulcer and lower-extremity amputation reduction as a stated Vision 2030 priority. Sovereign procurement of advanced GLP-1 therapy, CGM, and automated insulin delivery systems is no longer theoretical. The procurement window is open as of May 2026.
AimwellBio's edge is not more data. It is verified data. Every diabetes signal carries provenance, source method, and confidence. There is no hallucination tolerance for ministry-grade procurement or investment-committee decisions. Four independent audit agents check every brief before it is delivered.
Every corpus has a shape. The Johari model maps what this corpus knows, what it doesn’t yet track, and what’s been deliberately obscured in corporate disclosure.
Diabetes is repricing inside a regulatory, reimbursement, and sovereign-procurement window most portfolio teams will read about after it closes. The numbers below are the consequences of operating without an adversarial verification layer.
in capital reallocates per GLP-1 reimbursement decision cycle. Funds reading the formulary first reprice first. The 2025–2026 window is open as of May 2026.
KSA diabetes prevalence. Procurement windows for sovereign CGM and automated insulin delivery rollout open every 18 months. Vendors that miss the window wait.
typical lag between an FDA AdComm vote and equity repricing. Investors not on the dispatch sheet are pricing yesterday’s thesis.
second chances on a Vision 2030 ministry tender. Diabetic-care vendors that miss the procurement cycle wait until 2030.
Each entity is mapped into AIMN:ATLAS with scheduled-refresh SEC, ClinicalTrials.gov, PubMed, and manufacturer-disclosure coverage. Sovereign-tagged manufacturers across KSA, GCC, and MENA are flagged. Click any name to open its company dossier.
The Kingdom of Saudi Arabia carries an 18% diabetes prevalence — one of the highest in the world. The Ministry of Health has named lower-extremity amputation reduction a stated Vision 2030 priority. AimwellBio runs adversarial verification scoped to SFDA filings, MOH procurement cycles, and CGM and automated insulin delivery device approvals across the GCC.
The same infrastructure that gives an investment committee defensible diligence gives a ministry defensible procurement. No hallucination tolerance. Every signal source-cited. Every recommendation traceable to its evidentiary chain. Sovereign deployment is not theoretical.
Discuss sovereign deployment →New PubMed, ClinicalTrials.gov, and SEC EDGAR entries ingested on each corpus refresh cycle.
500 signals and 49 entities reflect the May 2026 indexed corpus. Counts update at the next scheduled rebuild, not in real time.
5-source adversarial PROCEED/DELAY/KILL verdict with confidence score. Member access. ~90s generation on demand.
Analyst estimate as of May 2026. Not recalculated on corpus refresh. Manually updated on major report releases.
IDF Diabetes Atlas 2023. Not dynamic. Updated when IDF publishes a new edition.
Every public and pre-IPO diabetes name carries reimbursement, AdComm, and clinical-readout risk. Aimwell delivers cited diligence before the conviction memo, not after it.
The diabetes landscape moves between earnings calls. Aimwell tracks pipeline, IP, and indication-expansion signals across the full coverage universe.
Real-world evidence and KOL movement on GLP-1, SGLT2, and CGM outcomes arrive faster than any single team can read. Aimwell structures the frontier into briefable units.
Designed For
Ozempic, Wegovy, and Mounjaro payer formulary tiering is shifting weekly. AIMN tracks PBM coverage decisions, step-edit protocol changes, and rebate-driven tier placements 60–90 days before they affect script volume.
Saudi MOH and GCC formulary committees run diabetes procurement on Ministry calendars, not calendar year. AIMN maps institution-specific approval timelines, SFDA registration status, and Vision 2030 diabetes program spending cycles.
Novo Nordisk and Eli Lilly GLP-1 gross-to-net compression is not visible in reported revenue. AIMN cross-references SEC filings with real-world formulary access data and manufacturing capacity signals before earnings.
CVOT data (LEADER, SUSTAIN-6, EMPA-REG) and real-world outcomes registries — 500+ diabetes signals including CT.gov trial updates, ADA/EASD guideline revisions, and post-market cardiovascular outcomes monitoring.
Ozempic, Wegovy, and Zepbound have restructured the $80B+ diabetes/obesity run-rate in 36 months. SGLT2 label expansions into CKD and HF have doubled the addressable clinical population. AimwellBio tracks 500 source-cited signals across 49 companies with adversarial validation — GLP-1 capacity constraints, SGLT2 formulary timelines, and GCC procurement cycles in one layer.
Ministry procurement or NDA briefing? Discuss sovereign deployment →